Merck & Co Inc acquires CN201, a promising bispecific antibody for B-cell diseases, from Curon Biopharmaceutical for $1.3 billion. CN201 shows potential in treating malignancies and autoimmune diseases.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing